Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367345 | 1.00 | ROCK1 (0.39) | ROCK1ROCK2KCNH2HRH3HTR3A | |
| SCHEMBL17967836 | 0.90 | ROCK1 (0.41) | ROCK1ROCK2KCNH2HRH3MKNK1 | |
| SCHEMBL3388421 | 0.77 | NOS3 (0.37) | ROCK1ROCK2KCNH2 | |
| SCHEMBL673109 | 0.76 | ROCK1 (0.40) | ROCK1KCNH2MKNK1MKNK2 | |
| SCHEMBL30673624 | 0.74 | HTR3A (0.38) | ROCK1ROCK2KCNH2HRH3HTR3A | |
| SCHEMBL9901829 | 0.74 | HTR3A (0.38) | ROCK1ROCK2KCNH2HRH3HTR3A | |
| SCHEMBL9900635 | 0.74 | HTR3A (0.38) | ROCK1ROCK2KCNH2HRH3HTR3A | |
| SCHEMBL9842899 | 0.73 | HTR1A (0.46) | — | |
| SCHEMBL12540028 | 0.72 | ESR2 (0.35) | — | |
| SCHEMBL12540026 | 0.72 | ESR2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864151-A | heterocyclic amine and application thereof | 利亘制药公司 | 2018-11-23 | — | — | CN | claimed |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | MC4R, MC5R, MC2R | ROCK1 4250/4885ROCK2 4214/4885KCNH2 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.